AngioDynamics (NASDAQ:ANGO) Stock: Insider Stephen Trowbridge Sells 1,720 Shares

AngioDynamics, Inc. (NASDAQ:ANGO) CFO Stephen Trowbridge sold 1,720 shares of the business’s stock in a transaction dated Wednesday, October 28th. The shares were sold at an average price of $12.17, for a total value of $20,932.40. Following the transaction, the chief financial officer owned 304,076 shares in the company, valued at $3,700,604.92. This represents a 0.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

AngioDynamics Stock Down 2.9%

AngioDynamics stock opened at $11.99 on Friday. The business has a 50 day moving average price of $14.18 and a two-hundred day moving average price of $12.47. AngioDynamics, Inc. has a 12 month low of $9.39 and a 12 month high of $16.29. The stock has a market cap of $504.18 million, a price-to-earnings ratio of -15.37 and a beta of 0.30.

AngioDynamics (NASDAQ:ANGO) last announced its quarterly earnings data on Thursday, October 8th. The medical instruments supplier reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.07. The company had revenue of $80.92 million for the quarter, compared to analyst estimates of $80.51 million. AngioDynamics had a negative return on equity of 4.49% and a negative net margin of 10.12%. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. On average, analysts expect that AngioDynamics, Inc. will post -0.27 earnings per share for the current fiscal year.

AngioDynamics News Roundup

Here are the key news stories impacting AngioDynamics this week:

• Positive Sentiment: Zacks Research raised its estimates for AngioDynamics’ Q2 2028 EPS to a loss of $0.03 from a loss of $0.07 and its FY2028 forecast to a loss of $0.16 from $0.17. The firm maintains a Hold rating.
• Positive Sentiment: AngioDynamics’ latest reported quarter exceeded expectations, with an adjusted loss of $0.04 per share versus the $0.11 consensus estimate and revenue of $80.92 million versus the $80.51 million forecast. Management’s FY2027 guidance remains a loss of $0.24 to $0.29 per share.
• Neutral Sentiment: Analyst opinion remains mixed. The stock carries an overall “Moderate Buy” rating, with a reported average price target of $19, but ratings range from Strong Buy to Sell. HC Wainwright has a Buy rating with an $18 target, while Canaccord Genuity maintains a Buy rating and a $20 target.
• Negative Sentiment: Zacks lowered several forecasts, including Q2 2027 EPS to a loss of $0.10 from $0.08, Q3 2027 to a loss of $0.10 from $0.05, FY2027 to a loss of $0.26 from $0.24, Q1 2028 to a loss of $0.08 from $0.06, Q3 2028 to a loss of $0.02 from $0.01, and Q1 2029 to a loss of $0.05 from $0.04. These revisions reinforce concerns about the company’s path to profitability.
• Negative Sentiment: CFO Stephen Trowbridge sold 25,335 AngioDynamics shares across transactions on October 28–29 for approximately $310,688. Although he still owns a substantial stake, the sales may weigh on sentiment by signaling limited near-term insider conviction. AngioDynamics CFO insider-selling report

Hedge Funds Weigh In On AngioDynamics

A number of hedge funds have recently modified their holdings of ANGO. BlackRock Inc. bought a new position in shares of AngioDynamics during the second quarter valued at $49,480,000. Weber Capital Management LLC ADV acquired a new stake in shares of AngioDynamics in the 2nd quarter valued at $17,649,392. Bastion Asset Management Inc. boosted its stake in shares of AngioDynamics by 17.4% in the 1st quarter. Bastion Asset Management Inc. now owns 1,313,002 shares of the medical instruments supplier’s stock valued at $14,107,000 after purchasing an additional 194,822 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of AngioDynamics by 3.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 948,815 shares of the medical instruments supplier’s stock worth $10,786,000 after purchasing an additional 32,476 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership grew its holdings in shares of AngioDynamics by 0.7% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 758,450 shares of the medical instruments supplier’s stock worth $8,624,000 after purchasing an additional 5,509 shares during the last quarter. 89.43% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on ANGO shares. Wall Street Zen lowered shares of AngioDynamics from a “buy” rating to a “hold” rating in a report on Saturday, October 10th. Weiss Ratings restated a “sell (d-)” rating on shares of AngioDynamics in a research note on Thursday, October 15th. Zacks Research raised shares of AngioDynamics from a “strong sell” rating to a “hold” rating in a report on Monday, October 5th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $20.00 price objective on shares of AngioDynamics in a report on Friday, October 9th. Finally, HC Wainwright decreased their target price on shares of AngioDynamics from $19.00 to $18.00 and set a “buy” rating on the stock in a research report on Tuesday, October 13th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $19.00.

About AngioDynamics

AngioDynamics, Inc is a medical technology company that develops and manufactures minimally invasive devices used in vascular access, peripheral vascular disease treatment, oncology and surgical procedures. Its products are designed to support physicians in diagnosing and treating patients while reducing the need for more invasive interventions.

The company’s portfolio includes the Auryon system for atherectomy and thrombectomy procedures, the NanoKnife system, which uses irreversible electroporation technology for the ablation of certain soft-tissue tumors, and devices for vascular access and the management of procedure-related complications.